Market Feasibility for a Engineering Biology Approach to Cell Therapy for Brain Cancer and Regenerative Medicine

脑癌和再生医学细胞治疗的工程生物学方法的市场可行性

• 批准号: 10074920
• 金额: $ 6.37万
• 依托单位: MIGRATION BIOTHERAPEUTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10074920
• 关键词: Market; Feasibility; Engineering; Biology; Approach

Glioblastoma (GBM) is the most aggressive and common brain tumour in adults. Even when a tumour can be surgically resected, recurrence often occurs caused by the migration of tumour cells left behind after surgery. These cells travel along healthy brain tissue to infiltrate deeper into the brain and inevitably reform the tumour again. There is no cure for GBM. Once diagnosed and operated on, patients have an expected survival of 14 months. Over the past 20 years, 70 new drugs and 1000 studies have failed in spite of 250,000 cases every year. Migration Biotherapeutics has developed an innovative bioengineered material that could unlock new therapeutic options in GBM. ALIGHT (tm) (Axon-Like Implantable Glioblastoma Harvesting Trap) is made of engineered nanofibers decorated with biological signal to attract GBM cells towards the device instead of infiltrating into healthy brain tissue, essentially acting as a 'decoy nerve.' This application offers a new paradigm, that of 'highjacking' the signals that guidethe migration of cancer cells. Different from other approaches, our proposals brings'cell biology as a therapy' and intends to exploit the natural migration of the cancercells towards new therapeutic options. There are multiple potential uses of ALIGHT and in this study, we will be challenging assumptions and mapping the opportunities for different development strategies. We will be exploring the development of a medical device to be implanted in the post-surgical cavity, which will attract residual cells for further treatment or direct them out of the brain through a catheter. We will also be assessing the demand and potential commercial opportunity for an in vitro assay to quantify drug candidates' effects on migration during the drug discovery process. Further applications in CNS have also been suggested to us by clinicians, and we hope to learn more about these opportunities in the course of this targeted research.

胶质母细胞瘤（GBM）是成年人中最具侵略性和常见的脑肿瘤。即使可以通过手术切除肿瘤，复发也经常是由于手术后留下的肿瘤细胞的迁移而引起的。这些细胞沿着健康的脑组织传播，以深入到大脑中，不可避免地再次改革肿瘤。 GBM无法治愈。一旦被诊断和操作，患者的生存期预期为14个月。在过去的20年中，尽管每年有25万例病例，但仍有70种新药和1000项研究失败。移民生物治疗药开发了一种创新的生物工程材料，可以在GBM中解锁新的治疗选择。下落（TM）（轴突样植入式胶质母细胞瘤收集陷阱）是由装饰有生物信号的工程纳米纤维制成的，可以吸引GBM细胞朝该装置，而不是浸入健康的脑组织中，实质上是“诱饵神经”。该应用程序提供了一种新的范式，即“高劫持”指导癌细胞迁移的信号。与其他方法不同，我们的建议将生物学作为一种疗法'，并打算利用cancercells的自然迁移到新的治疗选择。下落有多种潜在用途，在这项研究中，我们将具有挑战性的假设并绘制不同开发策略的机会。我们将探索要植入后腔腔的医疗装置的开发，该腔会吸引残留细胞以进一步治疗或通过导管将其引导出大脑。我们还将评估体外测定的需求和潜在商业机会，以量化候选药物在药物发现过程中对迁移的影响。临床医生也向我们提出了进一步的中枢神经系统申请，我们希望在这项有针对性的研究过程中更多地了解这些机会。